Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Sean M. Hays

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentCSPH-EOH General Op

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Aylward LL, Hays SM, Zidek A. Variation in urinary spot sample, 24?h samples, and longer-term average urinary concentrations of short-lived environmental chemicals: implications for exposure assessment and reverse dosimetry. J Expo Sci Environ Epidemiol. 2016 Oct 05. PMID: 27703149.
      View in: PubMed
    2. Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling. Toxicol Appl Pharmacol. 2016 Sep 01; 306:120-33. PMID: 27396814.
      View in: PubMed
    3. Aylward LL, Bachler G, von Goetz N, Poddalgoda D, Hays SM, Nong A. Biomonitoring Equivalents for interpretation of silver biomonitoring data in a risk assessment context. Int J Hyg Environ Health. 2016 Aug; 219(6):521-6. PMID: 27283208.
      View in: PubMed
    4. Hays SM, Macey K, Poddalgoda D, Lu M, Nong A, Aylward LL. Biomonitoring Equivalents for molybdenum. Regul Toxicol Pharmacol. 2016 Jun; 77:223-9. PMID: 26972837.
      View in: PubMed
    5. Aylward LL, Seiber JN, Hays SM. California biomonitoring data: Comparison to NHANES and interpretation in a risk assessment context. Regul Toxicol Pharmacol. 2015 Dec; 73(3):875-84. PMID: 26449396.
      View in: PubMed
    6. Terry C, Hays S, McCoy AT, McFadden LG, Aggarwal M, Rasoulpour RJ, Juberg DR. Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. Regul Toxicol Pharmacol. 2016 Mar; 75:89-104. PMID: 26472101.
      View in: PubMed
    7. Poet T, Ball N, Hays SM. Deriving Biomonitoring Equivalents for selected E- and P-series glycol ethers for public health risk assessment. Int J Hyg Environ Health. 2016 Jan; 219(1):88-100. PMID: 26475513.
      View in: PubMed
    8. Hays SM, Aylward LL, Blount BC. Variation in urinary flow rates according to demographic characteristics and body mass index in NHANES: potential confounding of associations between health outcomes and urinary biomarker concentrations. Environ Health Perspect. 2015 Apr; 123(4):293-300. PMID: 25625328; PMCID: PMC4384205.
    9. Arnold SM, Morriss A, Velovitch J, Juberg D, Burns CJ, Bartels M, Aggarwal M, Poet T, Hays S, Price P. Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition. Regul Toxicol Pharmacol. 2015 Mar; 71(2):235-43. PMID: 25543108.
      View in: PubMed
    10. Thompson CM, Seiter J, Chappell MA, Tappero RV, Proctor DM, Suh M, Wolf JC, Haws LC, Vitale R, Mittal L, Kirman CR, Hays SM, Harris MA. Synchrotron-based imaging of chromium and ?-H2AX immunostaining in the duodenum following repeated exposure to Cr(VI) in drinking water. Toxicol Sci. 2015 Jan; 143(1):16-25. PMID: 25352572; PMCID: PMC4274380.
    11. St-Amand A, Werry K, Aylward LL, Hays SM, Nong A. Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context. Toxicol Lett. 2014 Dec 01; 231(2):126-34. PMID: 25455445.
      View in: PubMed
    12. Smolders R, Koch HM, Moos RK, Cocker J, Jones K, Warren N, Levy L, Bevan R, Hays SM, Aylward LL. Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 1: metals. Toxicol Lett. 2014 Dec 01; 231(2):249-60. PMID: 25128590.
      View in: PubMed
    13. Hays SM, Macey K, Nong A, Aylward LL. Biomonitoring Equivalents for selenium. Regul Toxicol Pharmacol. 2014 Oct; 70(1):333-9. PMID: 25068883.
      View in: PubMed
    14. Koch HM, Aylward LL, Hays SM, Smolders R, Moos RK, Cocker J, Jones K, Warren N, Levy L, Bevan R. Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 2: personal care product ingredients. Toxicol Lett. 2014 Dec 01; 231(2):261-9. PMID: 24956590.
      View in: PubMed
    15. Aylward LL, Ramasamy S, Hays SM, Schoeny R, Kirman CR. Evaluation of urinary speciated arsenic in NHANES: issues in interpretation in the context of potential inorganic arsenic exposure. Regul Toxicol Pharmacol. 2014 Jun; 69(1):49-54. PMID: 24582650.
      View in: PubMed
    16. Becker RA, Hays SM, Kirman CR, Aylward LL, Wise K. Interpreting estrogen screening assays in the context of potency and human exposure relative to natural exposures to phytoestrogens. Birth Defects Res B Dev Reprod Toxicol. 2014 Feb; 101(1):114-24. PMID: 24391076.
      View in: PubMed
    17. Aylward LL, Hays SM, Smolders R, Koch HM, Cocker J, Jones K, Warren N, Levy L, Bevan R. Sources of variability in biomarker concentrations. J Toxicol Environ Health B Crit Rev. 2014; 17(1):45-61. PMID: 24597909.
      View in: PubMed
    18. Ball N, Bartels M, Budinsky R, Klapacz J, Hays S, Kirman C, Patlewicz G. The challenge of using read-across within the EU REACH regulatory framework; how much uncertainty is too much? Dipropylene glycol methyl ether acetate, an exemplary case study. Regul Toxicol Pharmacol. 2014 Mar; 68(2):212-21. PMID: 24378700.
      View in: PubMed
    19. Garcia HD, Hays SM, Tsuji JS. Modeling of blood lead levels in astronauts exposed to lead from microgravity-accelerated bone loss. Aviat Space Environ Med. 2013 Dec; 84(12):1229-34. PMID: 24459792.
      View in: PubMed
    20. Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, Rowlands JC, Whelan MP, Hays SM, Andersen ME, Meek ME, Reiter LW, Lambert JC, Clewell HJ, Stephens ML, Zhao QJ, Wesselkamper SC, Flowers L, Carney EW, Pastoor TP, Petersen DD, Yauk CL, Nong A. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci. 2013 Nov; 136(1):4-18. PMID: 23958734; PMCID: PMC3829570.
    21. Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays SM, Hixon JG, Harris MA. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol. 2014 May; 34(5):525-36. PMID: 23943231; PMCID: PMC4282340.
    22. Aylward LL, Kirman CR, Schoeny R, Portier CJ, Hays SM. Evaluation of biomonitoring data from the CDC National Exposure Report in a risk assessment context: perspectives across chemicals. Environ Health Perspect. 2013 Mar; 121(3):287-94. PMID: 23232556; PMCID: PMC3621178.
    23. Hays SM, Aylward LL, Driver J, Ross J, Kirman C. 2,4-D exposure and risk assessment: comparison of external dose and biomonitoring based approaches. Regul Toxicol Pharmacol. 2012 Dec; 64(3):481-9. PMID: 23017741.
      View in: PubMed
    24. Proctor DM, Suh M, Aylward LL, Kirman CR, Harris MA, Thompson CM, Gürleyük H, Gerads R, Haws LC, Hays SM. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere. 2012 Oct; 89(5):487-93. PMID: 22682893.
      View in: PubMed
    25. Aylward LL, Kirman CR, Adgate JL, McKenzie LM, Hays SM. Interpreting variability in population biomonitoring data: role of elimination kinetics. J Expo Sci Environ Epidemiol. 2012 Jul; 22(4):398-408. PMID: 22588214.
      View in: PubMed
    26. Becker RA, Hays SM, Robison S, Aylward LL. Development of screening tools for the interpretation of chemical biomonitoring data. J Toxicol. 2012; 2012:941082. PMID: 22518117; PMCID: PMC3306934.
    27. Hays SM, Aylward LL. Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents. Int J Hyg Environ Health. 2012 Feb; 215(2):145-8. PMID: 22192580.
      View in: PubMed
    28. Boogaard PJ, Aylward LL, Hays SM. Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH. Int J Hyg Environ Health. 2012 Feb; 215(2):238-41. PMID: 22177527.
      View in: PubMed
    29. Hays SM, Pyatt DW, Kirman CR, Aylward LL. Biomonitoring Equivalents for benzene. Regul Toxicol Pharmacol. 2012 Feb; 62(1):62-73. PMID: 22178585.
      View in: PubMed
    30. Kirman CR, Aylward LL, Blount BC, Pyatt DW, Hays SM. Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: application of chemical-specific screening criteria. J Expo Sci Environ Epidemiol. 2012 Jan-Feb; 22(1):24-34. PMID: 21989501.
      View in: PubMed
    31. Pyatt DW, Hays SM, English C, Cushing CA. United States Voluntary Children's Chemical Evaluation Program (VCCEP) risk assessment for children exposed to benzene. Toxicol Mech Methods. 2012 Feb; 22(2):81-104. PMID: 21859365.
      View in: PubMed
    32. Aylward LL, Lorber M, Hays SM. Urinary DEHP metabolites and fasting time in NHANES. J Expo Sci Environ Epidemiol. 2011 Nov-Dec; 21(6):615-24. PMID: 21847144.
      View in: PubMed
    33. Angerer J, Aylward LL, Hays SM, Heinzow B, Wilhelm M. Human biomonitoring assessment values: approaches and data requirements. Int J Hyg Environ Health. 2011 Sep; 214(5):348-60. PMID: 21764371.
      View in: PubMed
    34. Aylward LL, Becker RA, Kirman CR, Hays SM. Assessment of margin of exposure based on biomarkers in blood: an exploratory analysis. Regul Toxicol Pharmacol. 2011 Oct; 61(1):44-52. PMID: 21703323.
      View in: PubMed
    35. Aylward LL, Krishnan K, Kirman CR, Nong A, Hays SM. Biomonitoring equivalents for deltamethrin. Regul Toxicol Pharmacol. 2011 Jul; 60(2):189-99. PMID: 21466827.
      View in: PubMed
    36. Krishnan K, Adamou T, Aylward LL, Hays SM, Kirman CR, Nong A. Biomonitoring equivalents for 2,2',4,4',5-pentabromodiphenylether (PBDE-99). Regul Toxicol Pharmacol. 2011 Jul; 60(2):165-71. PMID: 21466829.
      View in: PubMed
    37. Kirman CR, Aylward LL, Hays SM, Krishnan K, Nong A. Biomonitoring equivalents for DDT/DDE. Regul Toxicol Pharmacol. 2011 Jul; 60(2):172-80. PMID: 21466830.
      View in: PubMed
    38. Hays SM, Aylward LL, Kirman CR, Krishnan K, Nong A. Biomonitoring equivalents for di-isononyl phthalate (DINP). Regul Toxicol Pharmacol. 2011 Jul; 60(2):181-8. PMID: 21466828.
      View in: PubMed
    39. Aylward LL, Hays SM. Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). Int J Hyg Environ Health. 2011 Jun; 214(3):179-87. PMID: 21440498.
      View in: PubMed
    40. Aylward LL, Hays SM. Consideration of dosimetry in evaluation of ToxCast™ data. J Appl Toxicol. 2011 Nov; 31(8):741-51. PMID: 21381051.
      View in: PubMed
    41. Boogaard PJ, Hays SM, Aylward LL. Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme. Regul Toxicol Pharmacol. 2011 Feb; 59(1):125-32. PMID: 20933039.
      View in: PubMed
    42. Hays SM, Aylward LL, Gagné M, Nong A, Krishnan K. Biomonitoring equivalents for inorganic arsenic. Regul Toxicol Pharmacol. 2010 Oct; 58(1):1-9. PMID: 20547195.
      View in: PubMed
    43. Aylward LL, Hays SM, Gagné M, Nong A, Krishnan K. Biomonitoring equivalents for hexachlorobenzene. Regul Toxicol Pharmacol. 2010 Oct; 58(1):25-32. PMID: 20547196.
      View in: PubMed
    44. Krishnan K, Gagné M, Nong A, Aylward LL, Hays SM. Biomonitoring Equivalents for triclosan. Regul Toxicol Pharmacol. 2010 Oct; 58(1):10-7. PMID: 20541577.
      View in: PubMed
    45. Krishnan K, Gagné M, Nong A, Aylward LL, Hays SM. Biomonitoring Equivalents for bisphenol A (BPA). Regul Toxicol Pharmacol. 2010 Oct; 58(1):18-24. PMID: 20541576.
      View in: PubMed
    46. Aylward LL, Kirman CR, Blount BC, Hays SM. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions. Regul Toxicol Pharmacol. 2010 Oct; 58(1):33-44. PMID: 20685286.
      View in: PubMed
    47. Aylward LL, Morgan MK, Arbuckle TE, Barr DB, Burns CJ, Alexander BH, Hays SM. Biomonitoring data for 2,4-dichlorophenoxyacetic acid in the United States and Canada: interpretation in a public health risk assessment context using Biomonitoring Equivalents. Environ Health Perspect. 2010 Feb; 118(2):177-81. PMID: 20123603; PMCID: PMC2831914.
    48. Pyatt D, Hays S. A review of the potential association between childhood leukemia and benzene. Chem Biol Interact. 2010 Mar 19; 184(1-2):151-64. PMID: 20067778.
      View in: PubMed
    49. Aylward LL, Hays SM, Gagné M, Krishnan K. Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). Regul Toxicol Pharmacol. 2009 Dec; 55(3):259-67. PMID: 19751787.
      View in: PubMed
    50. Hays SM, Aylward LL, Gagné M, Krishnan K. Derivation of Biomonitoring Equivalents for cyfluthrin. Regul Toxicol Pharmacol. 2009 Dec; 55(3):268-75. PMID: 19751788.
      View in: PubMed
    51. Aylward LL, Hays SM, Gagné M, Krishnan K. Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). Regul Toxicol Pharmacol. 2009 Dec; 55(3):249-58. PMID: 19751789.
      View in: PubMed
    52. LaKind JS, Naiman DQ, Hays SM, Aylward LL, Blount BC. Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999-2004. J Expo Sci Environ Epidemiol. 2010 May; 20(3):255-62. PMID: 19550438.
      View in: PubMed
    53. Aylward LL, Bodner KM, Collins JJ, Wilken M, McBride D, Burns CJ, Hays SM, Humphry N. TCDD exposure estimation for workers at a New Zealand 2,4,5-T manufacturing facility based on serum sampling data. J Expo Sci Environ Epidemiol. 2010 Jul; 20(5):417-26. PMID: 19491942.
      View in: PubMed
    54. Hays SM, Aylward LL. Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context. J Appl Toxicol. 2009 May; 29(4):275-88. PMID: 19115313.
      View in: PubMed
    55. LaKind JS, Hays SM, Aylward LL, Naiman DQ. Perspective on serum dioxin levels in the United States: an evaluation of the NHANES data. J Expo Sci Environ Epidemiol. 2009 May; 19(4):435-41. PMID: 18854873.
      View in: PubMed
    56. Garabrant DH, Aylward LL, Berent S, Chen Q, Timchalk C, Burns CJ, Hays SM, Albers JW. Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy. J Expo Sci Environ Epidemiol. 2009 Nov; 19(7):634-42. PMID: 18716607.
      View in: PubMed
    57. LaKind JS, Aylward LL, Brunk C, DiZio S, Dourson M, Goldstein DA, Kilpatrick ME, Krewski D, Bartels MJ, Barton HA, Boogaard PJ, Lipscomb J, Krishnan K, Nordberg M, Okino M, Tan YM, Viau C, Yager JW, Hays SM. Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S16-26. PMID: 18579271.
      View in: PubMed
    58. Aylward LL, Hays SM. Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S37-48. PMID: 18579270.
      View in: PubMed
    59. Aylward LL, Barton HA, Hays SM. Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S27-36. PMID: 18583006.
      View in: PubMed
    60. Hays SM, Aylward LL, LaKind JS, Bartels MJ, Barton HA, Boogaard PJ, Brunk C, DiZio S, Dourson M, Goldstein DA, Lipscomb J, Kilpatrick ME, Krewski D, Krishnan K, Nordberg M, Okino M, Tan YM, Viau C, Yager JW. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S4-15. PMID: 18583008.
      View in: PubMed
    61. Hays SM, Aylward LL. Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S57-67. PMID: 18583007.
      View in: PubMed
    62. Hays SM, Nordberg M, Yager JW, Aylward LL. Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S49-56. PMID: 18579269.
      View in: PubMed
    63. Aylward LL, LaKind JS, Hays SM. Biomonitoring Equivalents (BE) dossier for trihalomethanes. Regul Toxicol Pharmacol. 2008 Aug; 51(3 Suppl):S68-77. PMID: 18579267.
      View in: PubMed
    64. Aylward LL, Lakind JS, Hays SM. Derivation of biomonitoring equivalent (BE) values for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds: a screening tool for interpretation of biomonitoring data in a risk assessment context. J Toxicol Environ Health A. 2008; 71(22):1499-508. PMID: 18836925.
      View in: PubMed
    65. Pyatt DW, Aylward LL, Hays SM. Is age an independent risk factor for chemically induced acute myelogenous leukemia in children? J Toxicol Environ Health B Crit Rev. 2007 Sep-Oct; 10(5):379-400. PMID: 17687725.
      View in: PubMed
    66. Butterworth BE, Aylward LL, Hays SM. A mechanism-based cancer risk assessment for 1,4-dichlorobenzene. Regul Toxicol Pharmacol. 2007 Nov; 49(2):138-48. PMID: 17688981.
      View in: PubMed
    67. Barton HA, Chiu WA, Setzer RW, Andersen ME, Bailer AJ, Bois FY, Dewoskin RS, Hays S, Johanson G, Jones N, Loizou G, Macphail RC, Portier CJ, Spendiff M, Tan YM. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol Sci. 2007 Oct; 99(2):395-402. PMID: 17483121.
      View in: PubMed
    68. Hays SM, Pyatt DW. Risk assessment for children exposed to decabromodiphenyl (oxide) ether (Deca) in the United States. Integr Environ Assess Manag. 2006 Jan; 2(1):2-12. PMID: 16640311.
      View in: PubMed
    69. Pyatt DW, Hays SM, Cushing CA. Do children have increased susceptibility for developing secondary acute myelogenous leukemia? Chem Biol Interact. 2005 May 30; 153-154:223-9. PMID: 15878160.
      View in: PubMed
    70. Aylward LL, Brunet RC, Carrier G, Hays SM, Cushing CA, Needham LL, Patterson DG, Gerthoux PM, Brambilla P, Mocarelli P. Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. J Expo Anal Environ Epidemiol. 2005 Jan; 15(1):51-65. PMID: 15083163.
      View in: PubMed
    71. Aylward L, Kirman C, Cher D, Hays S. Re: analysis of dioxin cancer threshold. Environ Health Perspect. 2003 Aug; 111(10):A510. PMID: 12896864; PMCID: PMC1241631.
    72. Hays SM, Aylward LL. Dioxin risks in perspective: past, present, and future. Regul Toxicol Pharmacol. 2003 Apr; 37(2):202-17. PMID: 12726754.
      View in: PubMed
    73. Greene JF, Hays S, Paustenbach D. Basis for a proposed reference dose (RfD) for dioxin of 1-10 pg/kg-day: a weight of evidence evaluation of the human and animal studies. J Toxicol Environ Health B Crit Rev. 2003 Mar-Apr; 6(2):115-59. PMID: 12554432.
      View in: PubMed
    74. Aylward LL, Hays SM. Temporal trends in human TCDD body burden: decreases over three decades and implications for exposure levels. J Expo Anal Environ Epidemiol. 2002 Sep; 12(5):319-28. PMID: 12198580.
      View in: PubMed
    Hays's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)